In adults with ANCA-associated vasculitis (AAV), the amount of TWEAK protein in urine was about 50% as high when their disease was active as after six months of treatment, making it a useful biomarker for tracking disease activity, according to a new study from Sweden. The study further found…
News
Vertex Pharmaceuticals has signed a license agreement with Ono Pharmaceutical to develop and market povetacicept — a B-cell-targeting candidate for treating ANCA-associated vasculitis (AAV) and other autoimmune diseases driven by self-reactive antibodies and marked by signs or symptoms of kidney involvement — in Japan and South Korea.
Updated treatment guidelines from the British Society for Rheumatology favor rituximab over cyclophosphamide for active, relapsing ANCA-associated vasculitis (AAV), and set a standard maintenance treatment period of about 2-4 years after the disease has entered remission, or is determined to be well controlled. These recommendations are part of…
The selective immunosuppressive medication abatacept failed to significantly prevent treatment failure relative to a placebo in people with relapsing, non-severe granulomatosis with polyangiitis (GPA) taking part in a Phase 3 clinical trial, new data show. In addition to failing to meet this main goal of the study — called…
Up to two years of treatment with AstraZeneca’s Fasenra (benralizumab) helped adults with eosinophilic granulomatosis with polyangiitis (EGPA) that’s difficult to treat achieve and maintain disease remission, while reducing or eliminating the need for oral corticosteroids. That’s according to combined data from the completed head-to-head portion and the…
ANCA-associated vasculitis (AAV) therapy Tavneos (avacopan) is at least as effective as the glucocorticoid prednisone at inducing disease remission, reducing relapse rates, and improving kidney function and quality of life in patients with kidney involvement at treatment start. That’s according to new subgroup analyses from the Phase…
Facial palsy, or weakness of the facial muscles, is associated with a nearly 10 times higher risk of hearing loss with granulomatosis with polyangiitis (GPA), a type of ANCA-associated vasculitis (AAV), a single-center study suggests. Older age, along with ear or eye involvement, were also significant risk factors for…
Treatments for ANCA-associated vasculitis (AAV) have improved over time, but many patients still develop permanent organ damage, even though the extent of it has been less severe in recent years, a study in Turkey suggests. Mortality rates have remained largely similar over the years, with death more likely among…
Immune neutrophils and the weblike structures they release to trap and kill microbes — called neutrophil extracellular traps, or NETs — are key players in driving kidney damage in ANCA-associated vasculitis (AAV) and other diseases, a review study found. This points to neutrophils and NETs as potential targets for…
People diagnosed with ANCA-associated vasculitis (AAV) at age 75 or older may show more inflammation, higher rates of kidney involvement, or higher mortality than younger-onset patients based on their AAV type, a study in Japan finds. But immunosuppressive treatment plus standard corticosteroids appears to be more effective than corticosteroids…
Recent Posts
- Preparing for surgery with ANCA vasculitis is a team effort
- Serious heart disease seen early in newly diagnosed EGPA patients
- Gamma delta CAR T-cells are being tested to ‘reset’ AAV immune system
- Finding a little light on dark winter days is key with ANCA vasculitis
- Real-world data show high AAV remission rates with Tavneos